Benjamin Ebert, MD, PhD
Dana-Farber Cancer Institute named Benjamin Ebert, MD, PhD, president and chief executive officer (CEO) following Laurie H. Glimcher’s, MD, announcement that she plans to step down. Dr. Glimcher has held the position for eight years and will assume the title of president emerita.
Dr. Ebert is a well-known researcher, medical oncologist, and member of the American Society of Hematology (ASH). He is chair of the Department of Medical Oncology for Dana-Farber and will assume his new roles October 1, 2024.
“I’m extraordinarily honored to be selected as the next president and CEO of Dana-Farber and to build on the exceptional leadership and accomplishments of Laurie Glimcher,” Dr. Ebert said. “Together with our executive leadership team, I will continue to advance a patient-first model as we open this new chapter.”
Other roles Dr. Ebert currently holds include the George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School; Howard Hughes Medical Institute Investigator; and Institute Member of the Broad Institute of MIT and Harvard. Additionally, he was president of the American Society for Clinical Investigation (ASCI) in 2017.
In his research, Dr. Ebert focuses on hematologic malignancies, specifically myelodysplastic syndromes and clonal hematopoiesis. He is a member of countless medical societies and academies, including the National Academy of Medicine, the American Academy of Arts and Sciences, the ASCI, the Association of American Physicians, and the Academy of the American Association for Cancer Research.
Dr. Ebert has also been the recipient of several prestigious awards throughout his career, including the Meyenburg Prize for Cancer Research, the Sjöberg Prize from the Royal Swedish Academy of Sciences, the Korsmeyer Award from the ASCI, and the William Dameshek Prize from ASH — one of the Society’s highest honors.
“Ben has been a tremendously effective leader of our Department of Medical Oncology,” said Joshua Bekenstein, chair of the Dana-Farber board. “As we plan for the future of cancer care and discovery, we are confident that he will take on the new challenge as he has all others — with integrity, thoughtfulness, diligence, and compassion.”
Source: Dana-Farber, September 3, 2024.
